TDs clash after 'muppet' remark and mounting anger over potential €20-€50 pharmacy fees for vulnerable patients ...
Curis, Inc. , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from ...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present their Phase 1/2 study results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback